All In Biotech

Drug Trial Radar · NCT06067490

A Phase I Study of RC1416 Injection

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, andImmunogenicity of RC1416 Injection Via Subcutaneous Administration in Healthy Adult Volunteers.

Last checked: Nov 19, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 29, 2023

Primary completion

May 14, 2024

Study completion May 14, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • RC1416(SAD)Drug

    RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.

  • Placebo(SAD)Drug

    Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: up to 92 days
  2. Vital SignsTime frame: up to 92 days
  3. Laboratory TestsTime frame: up to 92 days
  4. ECGTime frame: up to 92 days
  5. Injection Site ReactionTime frame: up to 4 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.